XML 58 R44.htm IDEA: XBRL DOCUMENT
v3.23.2

Other Operating Income And Expenses (Tables) | 6 Months Ended
--- | ---
Jun. 30, 2023
Analysis of income and expense [abstract] |
Schedule of Other Operating Expenses | Other operating expenses for the first half of 2023 included €1,423 million of expenses related to Regeneron (versus €1,201 million in the first half of 2022), as shown in the table below.
(€ million) | June 30, 2023 (6 months) | June 30, 2022 (6 months) | December 31, 2022 (12 months)
Income & expense related to profit/loss sharing under the Monoclonal Antibody Alliance | (1,449) |  | (979) |  | (2,325) |
Additional share of profit paid by Regeneron towards development costs | 291 |  | 97 |  | 434 |
Reimbursement to Regeneron of selling expenses incurred | (260) |  | (216) |  | (476) |
Total: Monoclonal Antibody Alliance | (1,418) |  | (1,098) |  | (2,367) |
Immuno-Oncology Alliance | — |  | 36 |  | 16 |
Other (mainly Zaltrap® and Libtayo®) | 97 |  | (6) |  | 1,120 |
Other operating income/(expenses), net related to Regeneron | (1,321) |  | (1,068) |  | (1,231) |
of which amount presented in “Other operating income” | 102 |  | 133 |  | 1,147 |

X
- References No definition available. + Details
Name: | ifrs-full_AnalysisOfIncomeAndExpenseAbstract
Namespace Prefix: | ifrs-full_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Other Operating Expenses [Table Text Block] + References No definition available. + Details
Name: | sny_OtherOperatingExpensesTableTextBlock
Namespace Prefix: | sny_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration